This transcript has been edited for clarity. Akshay B. Jain, MD: Welcome, from San Diego. We are at the 83rd American Diabetes Association Scientific Sessions. I'm Akshay Jain, an endocrinologist from Surrey, British Columbia. With me is Professor Perkins from the University of Toronto. There's been some good information shared here, particularly about the Diabetes Control and Complications (DCCT) Trial which came out 40 years ago.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Harmel
Predictive Ketone Monitoring in Type 1 Diabetes: Not Only for Sick Days
This transcript has been edited for clarity. Akshay B. Jain, MD: Welcome from sunny San Diego, where we are at the 83rd American Diabetes Association Conference. With me is Professor Bruce Perkins from the University of Toronto. Professor Perkins, you've been doing a large amount of work in people with type 1 diabetes in your clinical trials, where you're looking at the possibility of predicting diabetic ketoacidosis (DKA) episodes. Can you share more about that? Bruce A.
New T2D Medications and Technology Offer 'Bespoke' Approach
This transcript has been edited for clarity. Akshay B. Jain, MD: Welcome from sunny San Diego at the 83rd Annual ADA Scientific Sessions. I'm Akshay Jain, an endocrinologist from Vancouver in Canada. Kevin Fernando, MSc: Hi. I'm Kevin Fernando. I'm a general practitioner with an interest in diabetes from Edinburgh, Scotland. Jain: Kevin, what are the key highlights that you've seen so far? Fernando: It's been a fantastic congress.
Flash CGM Sustainably Reduces Acute Hospitalizations in T2D
This transcript has been edited for clarity. Continuous glucose monitoring (CGM), especially flash CGM, is often prescribed to patients with diabetes, especially in those treated with basal-bolus insulin therapy. We did a study to evaluate acute hospitalization for diabetes events in patients with type 2 diabetes treated with basal-only insulin therapy. With this Social Security database, we were able to individualize 6000 patients with type 2 diabetes treated with basal-only insulin therapy.
Does Spinal Cord Stimulation Improve Diabetic Neuropathy?
This transcript has been edited for clarity. Good afternoon. I'm going to talk to you about the SENZA-PDN trial. This is a randomized controlled trial conducted in patients with peripheral diabetic neuropathy. It's a really important indication because these people suffer from large losses in their quality of life. Although we can treat these patients' pain with analgesics, often these therapies aren't effective.
Is Brain Insulin Important for Whole-Body Metabolism?
This transcript has been edited for clarity. Data from animal models showed that animals who didn't have any insulin in their brain developed a type 2 diabetes–like phenotype. We wondered if this is true in humans. Can it be that insulin acts in the human brain? Is this important for metabolism in the entire body? This is how I became interested in studying how insulin acts in the human brain. What we've learned so far is that, indeed, insulin acts in the human brain.
How Well Do Your Patients With Diabetes Cope With Change?
This transcript has been edited for clarity. We've been looking at the relationship between resilience, taken as close to the diagnosis of diabetes as possible, with future HbA1c and mental health status in patients with type 1 and 2 diabetes. When you consider two patients who arrive at your clinic with an identical HbA1c and similar clinical characteristics, it's really difficult to work out which patient is going to have better outcomes down the line.
'Urgent Low Soon' Alert Decreases Hypoglycemia After Exercise in T1D
This transcript has been edited for clarity. We know that hypoglycemia is a big problem for people with type 1 diabetes during exercise. This is due to increased insulin sensitivity and increased glucose requirements during exercise. We run a diabetes and physical activity clinic in Imperial College Healthcare NHS Trust, and we see many people with type 1 diabetes who wish to exercise but struggle with controlling their glucose levels.
Life Expectancy Shorter in Women With T2D vs Men
This transcript has been edited for clarity. It's great to be able to talk to you today about our for people with type 2 diabetes from Salford in the United Kingdom. We're very fortunate in that, within the population of Salford, we've been able to follow up with everybody who lives there for a 20-year period. Salford is an industrial city in the north of England. The people are predominantly of White European ethnicity.
Reducing Waste, Going Green With Diabetes Technology
This transcript has been edited for clarity. Ladies and gentlemen, we now have many different technologies for diabetes therapy. Diabetes technology has become a pillar of diabetes therapy. The inventions of continuous glucose monitoring (CGM) systems, patch pumps, and systems for automatic insulin delivery are helping patients around the globe every day improve their glucose control to avoid acute complications. This is great.
UKPDS Legacy Effects: The Importance of Treating Hyperglycemia Early
This transcript has been edited for clarity. I'm pleased to give an update on the UK Prospective Diabetes Study (UKPDS). This is the longest-running follow-up of a randomized controlled trial in type 2 diabetes. Those familiar with it may remember that the 20-year trial randomized patients to intensive blood glucose control with sulfonylurea/insulin, or in overweight patients, to metformin, compared with a conventional (primarily diet) policy.
Earlier Is Better: Treat Patients Before Type 2 Diabetes Develops
This transcript has been edited for clarity. One of the major problems we have to deal with in terms of the treatment of type 2 diabetes is to recognize that it's a very complicated disease with at least eight pathophysiologic disturbances, which I have referred to in my Banting Lecture as the "ominous octet." It should be very obvious that if we have eight pathophysiologic defects, no one drug can correct eight pathophysiologic defects.
Integrated Care and New Technologies in Type 1 Diabetes
This transcript has been edited for clarity. Type 1 diabetes is one of the diseases that is most challenging to treat if you are an endocrinologist. It is because type 1 diabetes has such a profound impact on the life of the people living with it. In recent years, we've had many new tools like insulin analogs, insulin pumps, glucose sensors, and also the hybrid closed loop systems. Still, the basis for the therapy of people with type 1 diabetes is the team approach.
Automated Insulin Delivery: The Next Generation of Research
This transcript has been edited for clarity. As many of you start to incorporate automated insulin delivery systems into your practice, I think it's exciting to talk about the future of automated insulin delivery systems. Just as cell phone manufacturers don't come out with one model of a cell phone and then stop innovating, the diabetes technology companies continue to build on the innovations that you've already seen.
What's New and Upcoming in CGMs?
This transcript has been edited for clarity. I'm very excited about the new continuous glucose monitoring (CGM) technologies that we're seeing achieve regulatory approval those that are due to come out and are currently under review. As we all know, sensor therapy vastly improves glycemia for persons living with diabetes, and we've seen that they flatten the curve of A1c achieved across a large age spectrum. How do we best allow this technology to penetrate clinical care?
Turn to PANTHER to Understand Diabetes Technology
This transcript has been edited for clarity. The PANTHER program is a resource for healthcare professionals looking to find practical, usable resources related to diabetes technology. It comes out of the Barbara Davis Center, where we have years and years of experience using new technologies, specifically automated insulin delivery systems, in the context of clinical trials. We had the opportunity to work on the clinical trials for the 670G, which was the first automated insulin delivery system.
Get the Complete Picture by Using CGM for Those With Diabetes
This transcript has been edited for clarity. Hello. Let's talk about the use of continuous glucose monitoring, or CGM, in primary care. In primary care and particularly in the management of our patients with diabetes, we're typically looking at logbooks. Logbooks can have great data, but we've learned that those data aren't always accurate or reflective of all that's going on with the patient. We also have the A1c, which is a great measure that's been around for some 30 years now.
Closing the Gap on Diabetes Care in Minority Populations
This transcript has been edited for clarity. Hello, everyone. As you might be aware, there's a big disparity gap in diabetes care in the minority population, including Latinos. I am a pediatric endocrinologist at the Barbara Davis Center, where we have been trying to close this gap. Some of the strategies that we have been implementing is the Barbara Davis Center Latino program, which is a culturally sensitive, language-appropriate, group-visit appointment.
A Brighter Future for Those With Type 1 Diabetes
This transcript has been edited for clarity. What an amazing time it is to be living with type 1 diabetes in 2022 and see the evolution of diabetes technology. I say this both personally and professionally. My brother was diagnosed with type 1 in 1977 in the days of urine glucose testing and animal insulin. I was diagnosed in 1984, the advent of blood sugar testing. Here we are today in 2022, both wearing hybrid closed-loop systems. I'm so proud of the role that JDRF played.
What Is the Weight Impact of Type 2 Diabetes Treatment?
This transcript has been edited for clarity. Diabetes treatment is currently focused on lowering blood glucose to reduce the risk for complications, particularly microvascular complications. Treatment approaches are also available to reduce the cardiovascular disease risk in people who are at high risk for or with established cardiovascular or kidney disease.
Do Sugary Drink Taxes Change Behavior?
This transcript has been edited for clarity. Today I'm going to talk about sugary drink taxes and the potential for these taxes to improve health outcomes. An unhealthy diet is a major cause of early death in the US, accounting for 1 in 5 deaths in this country. One dietary area that we've focused on as researchers and policymakers over the last decade or so is sugary drink consumption. On any given day, more than half of adults and children consume sugary drinks.
Let's Talk About Sex: Women With Diabetes Often Lose Interest
This transcript has been edited for clarity. Many women with type 1 and type 2 diabetes have sexual problems. In fact, up to approximately one third of women experience complaints of sexual desire, arousal, and even pain with sexual activity or just pareunia related to a variety of conditions, including the vulval and vaginal changes associated with menopause and beyond.
Put Down That Protein Bar and Opt for Nuts and Fruit Instead Original
This transcript has been edited for clarity. People with diabetes know the importance of nutrition. Today I want to talk about an eating strategy that can help people with type 1 or type 2 diabetes to achieve their glucose or glycemic goals. Many people are familiar with using low-carbohydrate or high-protein eating patterns to manage their glucose.
Turn 'Patients Into Experts' on Their Diabetes With CGM Use
This transcript has been edited for clarity. Continuous glucose monitoring (CGM) is revolutionizing the way we look at diabetes. We've gone from a 30,000-foot view in diabetes to an individualized, patient-centric glucose- or diabetes-related journey. There's been much talk about utility and the science behind it, but I'm passionate about going from knowing CGM to actually doing CGM in clinical practice. What we see in between is this large therapeutic inertia barrier.
How Does Exercise Affect Type 1 Diabetes?
This transcript has been edited for clarity. We've known for almost 100 years now that exercise is beneficial for people living with type 1 diabetes. It improves whole-body insulin sensitivity. It can reduce glucose levels, improve blood pressure, and help with weight management. Sometimes exercise can make glucose control much more difficult. It often causes low blood sugar, and from time to time, some forms of exercise may even cause high blood sugar.
National Clinical Care Commission offers T2D Recommendations
This transcript has been edited for clarity. In 2017, the Congress established the National Clinical Care Commission, and in 2018, it was convened by the Secretary of Health and Human Services. I had the privilege of chairing the National Clinical Care Commission. The purpose of the Commission was to leverage federal policies and programs to better prevent, treat, and reduce the complications of diabetes in the United States.
More Holistic Approach Needed for Hyperglycemia Management
This transcript has been edited for clarity. In the 2022 Management of Hyperglycemia consensus statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), the focus has shifted. Regarding the management of hyperglycemia, we feel a more holistic approach is needed.
New Advances in Obesity Management, but Challenges Remain
This transcript has been edited for clarity. My career has really been around clinical research in obesity and diabetes. I was part of the Diabetes Prevention Program, the Look AHEAD study, and the POUNDS LOST study. I helped develop the DASH diet. All of these studies focused on trying to help patients lose weight so that we can better treat these chronic diseases that are filling our offices.
Insulin Cap Legislation: Addressing the Challenges of Access
This transcript has been edited for clarity. We are now 101 years after the discovery of insulin. The goal when insulin was discovered and then spread throughout the world was that everybody would have access. That actually wasn't the case after the discovery of insulin, and sadly, it's not the case now.
Managing Chronic Kidney Disease in Patients With Diabetes
This transcript has been edited for clarity. The American Diabetes Association has recently released the 2022 Standards of Medical Care in Diabetes.
CGM in Hospitals as Standard of Care: What Have We Learned?
This transcript has been edited for clarity. As an adult endocrinologist, I've used continuous glucose monitoring, or CGM, many times in my patients to manage and get better control of their diabetes and glucose values. Over the past 4 or 5 years, I've been thinking about how we can do this better in a hospital environment where one third of all patients coming in have abnormal glucose levels.
New FDA Guidance on T2D Trial Design Provides Flexibility
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Perspective > Medscape Diabetes & Endocrinology > ADA 2021 COMMENTARY This transcript has been edited for clarity. The story of cardiovascular outcomes in diabetes is a fascinating one. There were new developments in the regulatory landscape that really drove the past 10 years of history.
With Tirzepatide, a 'Great Future' for Patients With T2D
This transcript has been edited for clarity. I'm here to talk about tirzepatide, a dual GIP/GLP-1 receptor agonists that's under investigation for the management of type 2 diabetes, obesity, and fatty liver disease. We're all very used to GLP-1 receptor agonists. They've been around for over a decade. These are medications such as dulaglutide or semaglutide, which is sort of the new frontier in the management of type 2 diabetes.
After Metformin, Which Drug Makes the GRADE?
This transcript has been edited for clarity. Hi. I'm delighted to be here today to tell you about the results of the GRADE diabetes study. Back in [2013], when GRADE launched, it was very clear that the first glucose-lowering medication to use in people with type 2 diabetes was metformin, but it really wasn't clear which medication to add to metformin. GRADE aimed to fill this evidence gap. How Is GRADE Different? GRADE aimed to be different from the other trials out there.
The Best Way to Prevent Type 2 Diabetes? Change Our Target
This transcript has been edited for clarity. Preventing type 2 diabetes is an extremely important goal that we should strive for. We know from some long-term studies that if we can prevent type 2 diabetes, we can prevent the risk for long-term consequences of diabetes. There's at least one trial that shows that 30 years after diabetes prevention, there's a lower risk for cardiovascular events and even death in people in whom diabetes was prevented. How do we identify preventive strategies?
Understanding COVID and Diabetes: Ominous Findings, Next Steps
Some of you may know that I worked at the Centers for Disease Control and Prevention for 20 years before coming to England, and I really focused on diabetes epidemiology. The COVID-19 pandemic, in addition to having a huge impact on life, has had a very unexpected and dramatic impact on the way we do our work, in the outlook for epidemiology and its role in diabetes.
Agents of Change: 4 Ways to Battle Social Determinants of Health
This transcript has been edited for clarity. We all know that social determinants of health affect health outcomes in a major way. We've recently become more aware of these social determinants of health with rising inequities in COVID-19 across the globe, and especially in diabetes.
'Stop Boring Patients': Tips for Engaging Diabetes Education
This transcript has been edited for clarity. The problem that we educators really need to address is the fact that most patients who probably need to get referred to diabetes education never even get referred. Of those who are referred, most of them never even make it. The critical issue I want to make sure we talk about is that the majority of people who make it to a formal, group-based, multisession diabetes education program don't complete the program. Retention rates are terrible.
The Future of Health Insurance for Patients With Diabetes
This transcript has been edited for clarity. It's hard to believe that we're now 10 years out from the institution of the Affordable Care Act. Since its inception, the Republican side has been interested in seeing its demise. The question in 2020 is: Where are we vis-à-vis the Affordable Care Act? Some Background One of the very first formal efforts to get rid of it was the Graham-Cassidy-Heller-Johnson bill that was presented in the Senate back in September 2017.
CGM Use in T1D: Don't Count Older Patients Out
This transcript has been edited for clarity. Older individuals with type 1 diabetes are at particular risk for hypoglycemia. This can be very serious. The consequences of hypoglycemia in older individuals include things like falls, fractures, cognitive impairment, and cardiovascular events. What can we do about this problem in older individuals with type 1 diabetes?
Irl Hirsch Reviews ADA Highlights With Anne Peters
This transcript has been edited for clarity. Anne L. Peters, MD: I'm here with a dear friend of mine, Dr Irl Hirsch, at the end of the virtual American Diabetes Association (ADA) Scientific Sessions to discuss a few of the findings from the meeting, as well as how we feel about virtual meetings. Irl, could you tell us a bit about some of the newer insulins? Irl B. Hirsch, MD: Yes, thank you. It's always good to be with you.
Insulin Can't Solve Everything: Adjunctive Therapies in T1D
This transcript has been edited for clarity. There's still a huge need for exploring adjunctive therapies in type 1 diabetes. This area of research is absolutely critical, and we're at an important juncture in this space where we're trying to figure out our way forward. What do we really want from adjunctive therapy in type 1 diabetes? We need to stop and pause, and think about the problems we're trying to solve. What metabolic consequences are we trying to deal with?
When to Refer Patients for Diabetes Education: New Guidance
This transcript has been edited for clarity. The 2020 Diabetes Self-management Education and Support (DSMES) consensus report is a summary of the current evidence on the value and benefits of diabetes self-management education services. Diabetes is a complex disease. Every day, people with diabetes have to make complicated, intricate decisions. How are they to learn what to do?
Female Sexual Dysfunction: If We Don't Ask, We Won't Know
This transcript has been edited for clarity. Female sexual dysfunction is common in people living with type 1 or type 2 diabetes, with 35%-71% of women living with either type 1 or type 2 diabetes experiencing female sexual dysfunction. And the problem is that we are not asking about it. Why do women with diabetes get female sexual dysfunction? The reasons are fairly obvious.
ADA 2020
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.
Going Beyond A1C: Improve Your Health with GMI and TIR
By Mark Harmel Mark Harmel, a Diabetes Care and Education Specialist, discusses the value of CGM reports, specifically the Glucose Management Indicator (GMI) and time in range (TIR) Since the A1C test was developed in the 1970s, people with diabetes have had to go to their doctor's office to get the test and see what their average blood sugars were. Those days are over, at least for those people who are using CGM.
Why Get an A1C Now That You Have GMI & TIR?
By Mark Harmel Mark Harmel, a Diabetes Care and Education Specialist, discusses the value of CGM reports, specifically the Glucose Management Indicator (GMI) and time in range (TIR) With diabetes management moving to telemedicine, many people with diabetes are asking, "How do I get an A1c?" But even before this pandemic, a number of leading researchers and clinicians were questioning the clinical value of the A1c, as it can be misleading based on genetic variability and certain medical...
Live From ADA 2016
Perspective > Medscape Diabetes & Endocrinology > American Diabetes Association (ADA) 76th Scientific Sessions Our editors and experts present highlights from the annual meeting as events unfold. Please share your own comments! Medscape Diabetes © 2016 WebMD, LLC Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape. Cite this: Christine Wiebe, Laurie Scudder, Mark Harmel, et. al. Live From ADA 2016 - Medscape - Jun 09, 2016.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack